Skip to main content

Table 3 Risk factors for raised CSF protein levels in patients with cryptococcal meningitis identified in alogistic regression analysis

From: Ventriculoperitoneal shunt is associated with increased cerebrospinal fluid protein level in HIV-infected cryptococcal meningitis patients

Factor

Number

Univariate

Multivariate

OR

95%CI

P value

OR

95%CI

P value

Age (years)

 > 50

9

0.6

0.1–4.5

0.657

   

 ≤ 50

77

      

Anticryptococcal therapy

 Contained AmB

53

0.4

0.0–3.7

0.405

   

 Did not contain AmB

34

      

HAART regimens

 Missing data

29

1.8

0.4–7.9

0.454

   

 INSTI

21

      

 Non-INSTI

37

      

VPS placement

 Yes

29

10.9

1.9–64.0

0.008

27.8

2.2–348.7

0.010

 No

57

      

CSF culture

 Missing data

7

      

 Positive

54

2.9

0.7–11.7

0.127

   

 Negative

26

      

Blood culture

 Missing data

1

      

 Positive

28

1.6

0.3–7.6

0.556

   

 Negative

58

      

Increase of CD4 count after 24 weeks(/mL)

 Missing data

45

      

 > 100

14

8.5

0.9–76.9

0.058

21.9

1.2–408.5

0.039

 ≤100

28

      

Initial CD4 count(/mL)

 Missing data

28

      

 > 20

26

0.3

0.1–1.4

0.112

   

 ≤ 20

33

      

Initial CSF ICH (mmH2O)

 Missing data

5

      

 > 300

52

1.4

0.3–5.9

0.633

   

 ≤ 300

30

      

Initial CD4 count (/mL)

 Missing data

28

      

 > 20

26

0.3

0.1–1.4

0.112

   

 ≤ 20

33

      

Initial CSF protein level (g/L)

 Missing data

7

      

 > 0.5

45

0.8

0.2–3.7

0.801

   

 ≤0.5

35

      

Initial CSF WBC (× 106/L)

 Missing data

10

      

 > 55

64

1.5

0.3–8.4

0.644

   

 ≤ 55

13

      

Time of HAART initiation

 Missing data

35

      

 Before 4 weeks

27

3.6

0.3–38.2

0.282

   

 After 4 weeks

25

      
  1. AmB Amphotericin B, HAART Highly active antiretroviral therapy, ICP intracranial pressure, INSTI Integrase strand transfer inhibitor, VPS ventriculoperitoneal shunt, OR odds ratio, CI confidence interval, ICH intracranial hypertension